Effects of systemic inflammation on relapse in early breast cancer

Abstract Chronic inflammation has been a proposed mechanism of resistance to aromatase inhibitors in breast cancer. Stratifying by HER2 status, a matched case-control study from the Wellness After Breast Cancer-II cohort was performed to assess whether or not elevated serum inflammatory biomarkers (...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicholas P. McAndrew, Lisa Bottalico, Clementina Mesaros, Ian A. Blair, Patricia Y. Tsao, Jennifer M. Rosado, Tapan Ganguly, Sarah J. Song, Phyllis A. Gimotty, Jun J. Mao, Angela DeMichele
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c1797f3e22424ecda689fbfd30194490
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c1797f3e22424ecda689fbfd30194490
record_format	dspace
spelling	oai:doaj.org-article:c1797f3e22424ecda689fbfd301944902021-12-02T14:19:03ZEffects of systemic inflammation on relapse in early breast cancer10.1038/s41523-020-00212-62374-4677https://doaj.org/article/c1797f3e22424ecda689fbfd301944902021-01-01T00:00:00Zhttps://doi.org/10.1038/s41523-020-00212-6https://doaj.org/toc/2374-4677Abstract Chronic inflammation has been a proposed mechanism of resistance to aromatase inhibitors in breast cancer. Stratifying by HER2 status, a matched case-control study from the Wellness After Breast Cancer-II cohort was performed to assess whether or not elevated serum inflammatory biomarkers (C-Reactive protein [CRP], interleukin-6 [IL-6], and serum amyloid A [SAA]) and/or the presence of a high-risk IL-6 promoter genotype were associated with recurrence of hormone receptor positive (HR+) early breast cancer. Estrogen levels were also measured and correlated with biomarkers and disease outcomes. CRP and SAA were significantly associated with an increased risk of recurrence in the HR+/HER2− group, but not the HR+/HER2+ group. Mean serum estrogen levels were non-significantly elevated in patients who relapsed vs. non-relapsed patients. Surprisingly, high-risk IL-6 promoter polymorphisms were strongly associated with HER2+ breast cancer relapse, which has potential therapeutic implications, as elevated intracellular IL-6 has been associated with trastuzumab resistance in pre-clinical models.Nicholas P. McAndrewLisa BottalicoClementina MesarosIan A. BlairPatricia Y. TsaoJennifer M. RosadoTapan GangulySarah J. SongPhyllis A. GimottyJun J. MaoAngela DeMicheleNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Nicholas P. McAndrew Lisa Bottalico Clementina Mesaros Ian A. Blair Patricia Y. Tsao Jennifer M. Rosado Tapan Ganguly Sarah J. Song Phyllis A. Gimotty Jun J. Mao Angela DeMichele Effects of systemic inflammation on relapse in early breast cancer
description	Abstract Chronic inflammation has been a proposed mechanism of resistance to aromatase inhibitors in breast cancer. Stratifying by HER2 status, a matched case-control study from the Wellness After Breast Cancer-II cohort was performed to assess whether or not elevated serum inflammatory biomarkers (C-Reactive protein [CRP], interleukin-6 [IL-6], and serum amyloid A [SAA]) and/or the presence of a high-risk IL-6 promoter genotype were associated with recurrence of hormone receptor positive (HR+) early breast cancer. Estrogen levels were also measured and correlated with biomarkers and disease outcomes. CRP and SAA were significantly associated with an increased risk of recurrence in the HR+/HER2− group, but not the HR+/HER2+ group. Mean serum estrogen levels were non-significantly elevated in patients who relapsed vs. non-relapsed patients. Surprisingly, high-risk IL-6 promoter polymorphisms were strongly associated with HER2+ breast cancer relapse, which has potential therapeutic implications, as elevated intracellular IL-6 has been associated with trastuzumab resistance in pre-clinical models.
format	article
author	Nicholas P. McAndrew Lisa Bottalico Clementina Mesaros Ian A. Blair Patricia Y. Tsao Jennifer M. Rosado Tapan Ganguly Sarah J. Song Phyllis A. Gimotty Jun J. Mao Angela DeMichele
author_facet	Nicholas P. McAndrew Lisa Bottalico Clementina Mesaros Ian A. Blair Patricia Y. Tsao Jennifer M. Rosado Tapan Ganguly Sarah J. Song Phyllis A. Gimotty Jun J. Mao Angela DeMichele
author_sort	Nicholas P. McAndrew
title	Effects of systemic inflammation on relapse in early breast cancer
title_short	Effects of systemic inflammation on relapse in early breast cancer
title_full	Effects of systemic inflammation on relapse in early breast cancer
title_fullStr	Effects of systemic inflammation on relapse in early breast cancer
title_full_unstemmed	Effects of systemic inflammation on relapse in early breast cancer
title_sort	effects of systemic inflammation on relapse in early breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/c1797f3e22424ecda689fbfd30194490
work_keys_str_mv	AT nicholaspmcandrew effectsofsystemicinflammationonrelapseinearlybreastcancer AT lisabottalico effectsofsystemicinflammationonrelapseinearlybreastcancer AT clementinamesaros effectsofsystemicinflammationonrelapseinearlybreastcancer AT ianablair effectsofsystemicinflammationonrelapseinearlybreastcancer AT patriciaytsao effectsofsystemicinflammationonrelapseinearlybreastcancer AT jennifermrosado effectsofsystemicinflammationonrelapseinearlybreastcancer AT tapanganguly effectsofsystemicinflammationonrelapseinearlybreastcancer AT sarahjsong effectsofsystemicinflammationonrelapseinearlybreastcancer AT phyllisagimotty effectsofsystemicinflammationonrelapseinearlybreastcancer AT junjmao effectsofsystemicinflammationonrelapseinearlybreastcancer AT angelademichele effectsofsystemicinflammationonrelapseinearlybreastcancer
_version_	1718391631071150080

Effects of systemic inflammation on relapse in early breast cancer

Ejemplares similares